A number of other research analysts have also weighed in on VKTX. Maxim Group lifted their price objective on shares of Viking Therapeutics from $35.00 to $50.00 and gave the company a buy rating in a research note on Thursday. Truist Financial reiterated a buy rating and issued a $32.00 price target on shares of Viking Therapeutics in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $33.38.
Viking Therapeutics Stock Performance
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). During the same period in the prior year, the firm earned ($0.26) earnings per share. As a group, analysts forecast that Viking Therapeutics will post -1.11 EPS for the current year.
Insider Buying and Selling at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $23.05, for a total value of $691,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Viking Therapeutics news, CFO Greg Zante sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $17.90, for a total transaction of $268,500.00. Following the sale, the chief financial officer now owns 180,730 shares in the company, valued at $3,235,067. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sarah Kathryn Rouan sold 30,000 shares of the company’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $23.05, for a total value of $691,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 374,079 shares of company stock valued at $9,729,653 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.
Hedge Funds Weigh In On Viking Therapeutics
A number of large investors have recently modified their holdings of VKTX. BlackRock Inc. raised its position in Viking Therapeutics by 237.9% in the 2nd quarter. BlackRock Inc. now owns 6,894,923 shares of the biotechnology company’s stock worth $111,767,000 after purchasing an additional 4,854,645 shares during the period. Vanguard Group Inc. increased its holdings in shares of Viking Therapeutics by 3.4% in the third quarter. Vanguard Group Inc. now owns 5,284,352 shares of the biotechnology company’s stock worth $58,498,000 after buying an additional 171,995 shares during the period. State Street Corp lifted its stake in shares of Viking Therapeutics by 2,039.4% in the 1st quarter. State Street Corp now owns 5,280,944 shares of the biotechnology company’s stock valued at $87,928,000 after acquiring an additional 5,034,102 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Viking Therapeutics by 21,586.9% during the 2nd quarter. Alliancebernstein L.P. now owns 2,961,561 shares of the biotechnology company’s stock valued at $48,007,000 after acquiring an additional 2,947,905 shares during the period. Finally, Balyasny Asset Management LLC grew its position in Viking Therapeutics by 1.2% during the 3rd quarter. Balyasny Asset Management LLC now owns 2,673,564 shares of the biotechnology company’s stock worth $7,272,000 after acquiring an additional 30,613 shares during the last quarter. 78.13% of the stock is owned by hedge funds and other institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
- Five stocks we like better than Viking Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Cloudflare results spark analysts reset: 25% upside ahead
- How to Invest in Cannabis, Step by Step
- Beyond Nvidia: The hidden stars with 200% earnings growth
- What is a Death Cross in Stocks?
- 3 large caps with RSIs that scream ‘oversold’
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.